肯博士的法氏囊.pptVIP

Lohmann Animal Health International Gainesville, Georgia, USA Technical Support Team Dr. Ken Takeshita (USA) Dr. Eric Lovell (USA) [Consultant] Dr. David Shapiro (USA) [Consultant] Dr. Greg Cutler (USA) [Consultant] Dr. Charles Hofacre (USA) [Consultant] Open (USA) Open (Latin America) Dr. Heike Scharr (Germany) Dr. van Dijk (Germany) Dr. Cher Yew (Singapore) Dr. Beatriz Cardoso (Brazil) Inactivated IBD Vaccines Bursal Tissue Origin (BTO) Chick Embryo Origin Cells (CEO) Tissue Culture Origin (TCO) Growing the IBD virus BTO vaccines started in UKEarly 1970’s Originated by group of UK veterinarians Were not happy with live IBD vaccines alone Probably chose BTO because: Easy to grow Grew to high titer UK government required strict potency tests Challenge of chicks from vaccinated parents Their work showed very strong protection in chicks from vaccinated parents ( to 4 weeks) Vaccine work was led by Dr. Box and produced by Glaxo BTO showed as better vaccine Longer duration of immunity when compared to TCO and CEO vaccines In USA, better able to protect against variant IBD strains Flock’s Vaccinated with Bursal Derived IBD ~ Better Titers Flock’s Vaccinated with Bursal Derived IBD ~ Better Protection BTO showed as better vaccine Production: Because NO virus adaptation is required, final output “matches” seeds/”matches” challenge Viral growth Very high titers because virus is “home” Potentially other immune factors produced So called “bursin” Incomplete viral particles Virus content which is “hidden” from normal assay BTO became widely used First used in breeders as only IBD vaccine and/or as part of program with live progeny vaccination 1st BTO vaccines were 2x cost of TC or CEO vaccines As time moved from 1970’s to 1980’s UK Europe began to decline usage Regulatory issues Fear of CAV in the vaccines Animal welfare (using chickens to make vaccine) Interference with live vaccines USA moved solidly to BTO IBD vaccines Used alone